r/wallstreetbets
The Great Rotation: money is fleeing AI bagholders and waddling straight into fat-loss drugs
Money is rotating out of AI stocks into healthcare, specifically GLP-1 weight-loss drugs like NVO and LLY.
- Macro rotation from AI/tech to defensives as AI capex ROI is questioned.
- GLP-1 market is expanding with new oral formulations, attracting new patients.
- Strong fundamental growth and market dominance in the weight-loss drug sector.
- AI trade is wobbling and tech sector is experiencing consecutive red days.
- GLP-1 companies face potential sales declines in future guidance.
Alright regards, gather round. Something actually happened this week besides my puts expiring worthless.
The setup: Nasdaq just printed its 5th straight red day. The AI infinite-money-glitch trade is wobbling. OpenAI is reportedly thinking about pushing its IPO to next year, and suddenly everyone remembered that “spend $500B on GPUs and figure out revenue later” might not be a plan. Chips got smoked. Apple and Microsoft eating losses on their own drama.
So where did the smart money run? Defensives. And healthcare specifically caught a real bid, second-best sector on the week with the equal-weight index climbing, meaning it’s not just 7 megacaps holding the tape up anymore. This is what a rotation looks like before it’s obvious.
Enter the fat-loss summer body cartel. 💊
Novo (NVO) is the degenerate value play here. Stock got absolutely beaten like it owed someone money, down \~65% from the 2024 top, max drawdown over 50% in March after a CagriSema miss and two guidance cuts. But the tape is turning:
• Oral Wegovy lands in the UK July 6th. First GLP-1 pill for weight loss in Europe.
• Chemist4U alone reportedly has a 10,000+ waitlist, and \~75% have NEVER touched a GLP-1. That’s not stealing Lilly’s customers, that’s growing the whole pie.
• EU gave the pill a positive regulator opinion in May, EC approval pending, launches in Germany / Denmark / UK in 6. Juli. Already.
• It bounced \~6% on the UK approval and closed Friday green while tech bled.
Eli Lilly (LLY) is still the 800lb gorilla, don’t get it twisted. Mounjaro + Zepbound did \~$36B last year and Lilly’s guiding to \~28% growth while Novo guides to a decline. Their oral, Foundayo, is ramping slower because it’s a new molecule/brand, and orforglipron is the wildcard. If you want the quality compounder, it’s LLY. If you want the beaten-down turnaround lottery ticket, it’s NVO.
The bear case (because I’m not totally smooth-brained): Novo’s own 2026 guidance is a sales DECLINE of 4-12%. US pricing is eroding. Lilly is taking share. Analysts are mostly Hold (like 5 Buy / 9 Hold, zero Sell, aka “we have no idea”). The pill demand is real but the metric that matters is whether people stay on it through the dose ramp.
The catalyst: Novo Q2 earnings August 5th. Pill retention numbers will either send it or end it.
TL;DR: AI bubble leaking air, money rotating defensive, healthcare bid, and the GLP-1 pill war is going global. NVO = turnaround YOLO, LLY = the safe-ish chad play.
Positions: long both because I refuse to pick a side in a knife fight. NFA, I eat crayons. 🖍️🐂
No way bro used AI to make a post about money leaving AI
"You are absolutely right"
"This is an exceptionally sharp analysis"
Llms are never wrong and Claude told me it’s safe to drink peroxide to cleanse my body
AI slop. No convictions, paper hands, changes mind like they’re the front runner to an old Katy Perry song.
Puts? Worthless
Bear thesis? Liquidated
Long term outlook? “Just buy this pharmaceutical company bro I swear they’re gonna pass FDA trials.”
I finally pulled the trigger. After watching my tech portfolio get absolutely hammered while I sat there holding bags of "AI-integrated" garbage, I decided enough was enough. I spent the better part of the weekend drowning in clinical trial data and European supply chain projections, convinced that if I could just time the GLP-1 transition right, I could finally climb out of the hole. I was deep in the zone, spreadsheets open, running sensitivity analysis on the Q2 guidance until my eyes were burning.
Just as I was about to execute the trade, there was a knock at the door. I opened it to see this little old lady in a dusty coat. She started rambling about pharmaceutical patent expiration dates and global distribution bottlenecks in a way that sounded strangely informed. Intrigued, I invited her in to take a look at my due diligence, thinking maybe she actually knew something. She walked over, stared at my terminal for a long moment, then tilted her head and said, "I have the inside track on the Q2 earnings call, but it’s gonna cost you about tree fiddy."
I took a good hard look at her, squinting as she seemed to grow about 500 feet taller right there in my living room. It wasn’t a grandmother! it was that goddamn Loch Ness Monster! I yelled, "Dammit, Loch Ness Monster, get out of my house! I ain't givin' you no tree fiddy!"
Your post? Yeah...
Just put the fries in the bag my mouth
https://preview.redd.it/7axmiggb7s9h1.png?width=1024&format=png&auto=webp&s=e7824775d318764def583dc8d3409e686c88c1ed
I quit drinking a month ago, my hands shake from 0DTEs now not liquor
Funny diamond hands dont shake they hold
GLP-1 pricing is a race to the bottom.
Disagree.
The stuff coming out in 2028 is crazy shit. I’m on one now for alcohol reduction and it’s changed my life.
Not to mention. How stupid fit i am getting
I'm glad that it's working out for you, but the reasons that the prices are falling do not indict the efficacy of the product.
People would literally rather inject gray market peptides from China than pay these companies.
Anything is better than moderate physical activity and making better food choices when insurance won't cover the drugs.